Christopher Fitzpatrick

Christopher Fitzpatrick has extensive experience in medical affairs within the neurology field, specializing in rare genetic epilepsy at Marinus Pharma since 2023, and previously in headache and pain medicine at Impel Pharmaceuticals from 2021 to 2023, as well as AbbVie from 2019 to 2021. Fitzpatrick's academic background includes a Ph.D. in Neuroscience from the University of Michigan, complemented by teaching as an adjunct instructor and engaging in research roles at prestigious institutions, including the University of Michigan Medical School and Wayne State University.